Effects of Single Oral Dose Dapagliflozin QT Study | NCT00688493 | Trialant

Effects of Single Oral Dose Dapagliflozin QT Study | NCT00688493 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
20 mg single dose of dapagliflozin	Experimental	20 mg dapagliflozin	Drug: Dapagliflozin Drug: Moxifloxacin Drug: Placebo to match moxifloxacin and dapagliflozin
150 mg single dose of dapagliflozin2	Experimental	150 mg dapagliflozin	Drug: Dapagliflozin Drug: Moxifloxacin Drug: Placebo to match moxifloxacin and dapagliflozin
400 mg single dose of moxifloxacin	Active Comparator	Moxifloxacin	Drug: Dapagliflozin Drug: Moxifloxacin Drug: Placebo to match moxifloxacin and dapagliflozin
Placebo	Placebo Comparator	Placebo	Drug: Dapagliflozin Drug: Moxifloxacin Drug: Placebo to match moxifloxacin and dapagliflozin

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Dapagliflozin	Drug	3 x 50 mg tablets, single oral dose	150 mg single dose of dapagliflozin2 20 mg single dose of dapagliflozin 400 mg single dose of moxifloxacin

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Electronic measures of heart beats		ECGs (electronic measures of the heart) are taken at scheduled times during the 3 days after receiving each dose of study medication

Secondary Outcomes

Measure	Description	Time Frame
Blood levels of dapagliflozin following single 20 mg and 150 mg doses in healthy volunteers		At scheduled times during the 3 day periods following dosing during each of the 4 study periods
Safety and tolerability of dapagliflozin		Screening through completion of the study

Contacts/Locations Module

Intervention Browse Module